SocialPicks Sentiment:
** v.s.
other stocks
|
This Quarter's Sentiment:
|
|
|
OSIR Analysis & Videos »
OSIR: Bull or Bear?
Stem Cell Index Surges in Past Week
OSIR
|
|
|
-49.96%
in
183 days
<> The stem cell trade was back in a big way over the past week, with several stocks in the <font> ETF Innovators Stem Cell Index </font> registering impressive gains, compared to market and biotech ETF benchmarks such as the S&P 500 SPDR (NYSE:SPY) +6%, iShares Nasdaq Biotech (NASDAQ:IBB) +2%, SPDR S&P Biotech (NYSE:XBI +4%). Hot stocks over the past week among the 40 component companies in the stem cell index include NeoStem (AMEX:NBS) +52.2%, Cytori Therapeutics (NASDAQ:CYTX) +37%, and Geron (NASDAQ:GERN) +22%. Two other widely followed stocks from the index registered smaller gains,...
|
FDA, Clinical Trial Calendar Updates: Genzyme, Isis, Osiris, Roche, Watson
OSIR
|
|
|
+7.66%
in
18 days
(closed on 05/10/09)
<> The FDA Calendar includes companies with pending new drug, biological agent, or medical device new product decisions at the FDA sorted by their PDUFA decision deadline dates while the Clinical Trial Calendar encompasses pending clinical trial results (with a focus on late-stage, Phase 3 trials), pending new submissions to the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, sBLA filings), and pending re-submissions to the FDA for complete r...
|
Osiris Completes Phase 3 Enrollment, Initiates FDA Filing
OSIR
|
|
|
-6.27%
in
5 days
(closed on 04/22/09)
Posted by: Mike Havrilla in Untagged on Apr 17, 2009 <!-- Post Teaser Text --> <> On 4/17/09, OSIR announced that it has successfully completed patient enrollment in its pivotal, Phase III trial evaluating Prochymal as a first-line treatment for acute graft vs. host disease (GvHD), a life-threatening complication of bone-marrow transplantation. Prochymal Phase 3 Results for graft-vs-host disease (GvHD) Expected 2H09 for both trials. <> The double-blind, placebo-controlled trial enrolled 190 patients from 52 leading transplant centers ac...
|
Stem Cell Index: YTD Analysis, Banking on NeoStem
OSIR
|
|
|
+6.87%
in
6 days
(closed on 04/17/09)
<> <> <> <!-- <td valign="top" width="1%"> <img src="/images/quotes.gif" /> </td> --> <> <> Related Tickers: NBS, IART, OSIR, STEM, GE, XLV, IBB, XBI, PBE, SPY Disclosure: No Positions <> The ETF Innovators Global Stem Cell and Regenerative Medicine Index tracks the performance of 40 stem cell and regenerative medicine companies on a globa...
|
FDA and Clinical Trial Calendar Updates
OSIR
|
|
|
-11.57%
in
15 days
(closed on 04/11/09)
<> The FDA Calendar includes companies with pending new drug, biological agent, or medical device new product decisions at the FDA sorted by their PDUFA deadline dates. The entries are updated on a daily basis as new information becomes available with a total of 106 entries through 3/27/09. The FDA Calendar includes the following information: company name...
|
Analysis of Global Stem Cell Index YTD
OSIR
|
|
|
+8.07%
in
6 days
(closed on 03/10/09)
The accompanying table includes statistics for the 40 companies in the ETF Innovators Global Stem Cell and Regenerative Medicine Index , which is down 13.8% at a value of 3,387 from a 2/22/09 inception date value of 3,928. The index is down 30.6% over the past year on an equal-weight basis, compared to losses of 31.2% for the Healthcare Sector SPDR (XLV), 19% for iShares Nasdaq Biotech (IBB), 14.7% for SPDR S&P Biotech (XBI), 29.7% for PowerShares Biotech & Genome (PBE), and 46.1% for the S&P 500 SPDR (SPY). <> Below is a profile for each company, including a summary of their b...
|
Bullish on OSIR ...
OSIR
|
|
|
-59.83%
in
252 days
Osiris Therapeutics, Inc., a biotechnology company, commercializes stem cell products from adult bone marrow in the United States. It develops and markets products to treat medical conditions in the inflammatory, orthopedic, and cardiovascular areas. The companyÂ’s products include Prochymal, which is in phase III clinical trials for the treatment of steroid refractory Graft versus Host Disease (GvHD), acute GvHD, and CrohnÂ’s disease; in phase II clinical trials for the treatment of Type I diabetes and acute myocardial infarction; in preclinical stage for the treatment of acute radiation s...
|
Global Stem Cell and Regenerative Medicine Index
OSIR
|
|
|
-10.68%
in
7 days
(closed on 03/04/09)
By Mike Havrilla on 2/25/09
www.BioMedReports.com The ETF Innovators Global Stem Cell and Regenerative Medicine Index includes 40 companies with market caps less than $1B at the index inception and the total market value of the index will be tracked as a gauge of investor and trader sentiment toward stem cell companies from a starting value of 3,928 on 2/22/09 and current value of 3,860 as of 2/25/09 - down 1.7% from the closing value last week. <> <> The index is down 23.8% over the past year on an equal-weight basis, compared to losses of 21.4% for the Heal...
|
Global Stem Cell Index Down 9% Last Week
OSIR
|
|
|
-0.47%
in
3 days
(closed on 02/25/09)
Global Stem Cell Index Down 9% Last Week By Mike Havrilla on 2/21/09 The ETF Innovators Global Stem Cell and Regenerative Medicine Index of 40 companies with market caps less than $1B at the index inception lost 9% of its value last week and is down 24.8% over the past year on an equal-weight basis, compared to losses of 21.6% for the Healthcare Sector SPDR (XLV), 8.4% for iShares Nasdaq Biotech (IBB), 4.5% for SPDR S&P Biotech (XBI), 19.9% for PowerShares Biotech & Genome (PBE), and 41.6% for the S&P 500 SPDR (SPY).
|
Global Stem Cell and Regenerative Medicine Index
OSIR
|
|
|
-7.38%
in
4 days
(closed on 02/22/09)
Global Stem Cell and Regenerative Medicine Index By Mike Havrilla on 2/17/09 <> The table at my website link below includes 40 companies in the ETF Innovators Global Stem Cell and Regenerative Medicine Index, which represents an expansion of the Emerging Stem Cell Index I have written about previously . The expanded global index includes companies with market caps less than $1B at the index inception with a total market value of $3,814 as of the close today. As previously, I will track the total market value for a more comprehensive gauge of investor sentiment...
|
Healthcare Investing Trends in '09 and Beyond
OSIR
|
|
|
-1.01%
in
9 days
(closed on 02/16/09)
<> While the departure of Tom Daschle and concerns over rising unemployment and the global economic slowdown may hamper many of President Obama's plans for healthcare reform; there are several growth trends within the sector outlined below which are poised to benefit in 2009 and beyond. Follow any of the links below for more information on the new ETF Innovators indexes and exchange-traded fund ideas for the sector.
Global Health IT : The top five rated companies include Swiss telemedicine firm Card Guard (CDGUF) – a pro< />< />< />< /><>< />< />< />< /><><>< />< /><>< />< />< />< /><>...
|
New Emerging Stem Cell Index
OSIR
|
|
|
+3.55%
in
5 days
(closed on 02/07/09)
New Emerging Stem Cell Index Shares of Geron (GERN) and other well known stem cell and regenerative medicine stocks such as Osiris Therapeutics (OSIR) and StemCells (STEM) have been soaring since the FDA allowed human clinical testing for Geron's embryonic stem cell treatment candidate for spinal cord injuries. <> The table at my website link below highlights 25 U.S.-listed stem cell and regenerative medicine companies with market caps of below $200M which are included in the ETF Innovators Emerging Stem Cell Index. The companies are also listed below in descending ...
|
Index to Track New Era for Stem Cell Cos.
OSIR
|
|
|
+2.67%
in
10 days
(closed on 02/02/09)
Index to Track New Era for Stem Cell Cos. Shares of Geron (GERN) are soaring today by more than 40% on FDA approval to begin human clinical testing this summer for an embryonic stem cell treatment for spinal cord injuries. The approval comes just days after the new administration took office, breathing new life into related companies such as StemCells (STEM), Aastrom Biosciences (ASTM), and others tracked in the ETF Innovators Cosmetic & Reconstructive Medicine Index. <> This index and new ETF idea represents a first-to-market idea to provide investors with an excha...
|
People Bullish on OSIR
People Bearish on OSIR
|
ROCK-STAR INVESTORS
|
|
POPULAR STOCKS
|
|
TODAY'S HEADLINES
|
|
TODAY'S TOP PICKS
|
|
|
| StreetInsider.com on OSIR |
Be the first to start a discussion and earn 2 points.
More Resources
|
About Osiris Therapeutics Inc.
- Answers.com
